Skip to main content

Roche investing an additional 1.2 billion Swiss francs in Basel

| News

Roche investing an additional 1.2 billion Swiss francs in Basel


Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment will be used to finance another research and development building and the modernization of molecule production, in addition to a building for the Institute of Human Biology.

Significant investments are being made in the northern part of the site (image: Roche)

Roche announced its plans for the further modernization of the infrastructure at its Basel site. To this end, the pharmaceutical firm will be investing 1.2 billion Swiss francs to upgrade the northern part of the site. Since 2014, the company has already invested a sum of 3 billion Swiss francs in its Basel location.

The investment of 1.2 billion Swiss francs will be used to build another 72-meter-high, 13-story research and development building, among other things. The aim here is to provide attractive laboratory workstations for up to 450 researchers. Moreover, a new production building is to be built for the synthetic and chemical production of medicines. The existing building will also be refurbished and expanded, while the plans additionally include a new building for the Institute of Human Biology with space for up to 250 researchers. For this, an existing building will be converted and fully remodeled.

Big plans also for the southern part

“The new buildings will expand the infrastructure for future innovations along the entire pharmaceutical value chain, from research to production”, comments Jürg Erismann, Head of the Basel site, in the press release. He adds: “This is another clear commitment to the Basel research and production site and to Switzerland”. It is expected that the construction work on the research building and other building renovations will be completed by 2030.

As Roche explains in a video covering its site development plans in Basel, wide, generously proportioned green spaces will be created in the southern part of the area. To this end, the research and office buildings will be removed. According to a press release, the cantonal government of the canton of Basel-Stadt also approved a corresponding development plan on November 17. These plans also include a central building for visitors and employees in the park and a possible third high-rise building depending on Roche’s needs in the future.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

Paradigm shift in pain management

Pain is a crucial sensation for survival, but it can also drive us to depression and long-term suffering if not...
Read More

BOOM Summit in Basel accelerates health technology

The BOOM Summit at Messe Basel in April 2024 will be a completely new kind of healthcare conference. The first...
Read More

Investors stump up 3.7 million Swiss francs in Onena Medicines

Onena Medicines has secured an investment of 3.7 million Swiss francs. The portfolio company of the biotech startup incubator BaseLaunch...
Read More

Do you have a question? We'd like to hear from you.